基因改造动物市场－全球产业规模、份额、趋势、机会和预测：按产品、PCR、技术、应用、模式生物、最终用户、地区和竞争格局划分，2021-2031年

全球基因改造动物市场预计将从2025年的41.8亿美元成长到2031年的76.3亿美元，复合年增长率（CAGR）为10.55%。该行业涉及将基因经过人为改造以表达特定所需性状的生物体商业化和应用，用于研究和生物生产。推动这一增长的关键因素包括：对用于研究人类慢性疾病的预测性动物模型的需求日益增长，以及生物製药领域对重组蛋白和单株抗体的需求不断增加。此外，基因编辑技术的持续进步也成为重要的成长引擎，使得人们能够精确地建立能够重现复杂生理状态的动物模型，而这些复杂生理状态对于可靠的药物发现和开发至关重要。

儘管存在这些有利因素，但由于严格的伦理法规和公众对动物福利日益增长的关注，市场仍面临着许多障碍，这可能导致监管核准延迟并增加遵循成本。然而，科学界仍高度依赖这些模型进行重要研究。 2024 年《了解动物研究》报告的数据显示，英国45% 的受监管科学程序都用于创造或培育基因改造动物，凸显了该领域在生物医学创新中持续且重要的作用。

市场驱动因素

基因组编辑和基因工程技术的突破性进展是全球基因改造动物市场的主要驱动力。 CRISPR-Cas9等精准工具的整合彻底改变了我们对动物进行特定基因改造的能力，使得培育具有与人类相容的器官和精准疾病表型的生物体成为可能。这项技术的成熟吸引了大量投资，尤其是在异种移植应用领域，基因改造猪是可行的器官来源。例如，eGenesis公司于2024年9月宣布已获得1.91亿美元的D轮资金筹措，用于推进其基因工程猪肾候选药物进入首次人体临床试验，充分展现了市场对这些基因组平台的强大商业性信心。

同时，对预测性临床前人类疾病模型日益增长的需求正显着推动市场发展。随着复杂慢性疾病的增多，製药研发人员需要先进的体内系统来筛检潜在治疗方法，并避免后期临床试验失败。 2024年1月，美国癌症协会（ACS）发布的《2024年癌症事实与数据》报告预测，美国新增癌症病例数将首次超过200万例，凸显了对先进癌症模型的迫切需求。这种疾病负担正促使大量资金投入利用基因改造生物的药物研发管线。例如，默克在2024年2月报告称，其2023年全年研发总支出将达到305亿美元，这反映了对生物医学创新的大力支持。

市场挑战

全球基因改造动物市场成长的主要障碍在于严格的伦理法规以及公众对动物福利日益增长的关注。世界各地的监管机构正在推出更严格的标准，要求相关机构接受全面的伦理审查，并严格遵守替代、减少和优化原则。这些合规要求需要在监测和记录方面投入大量资金，导致研发週期延长、营运成本增加，最终阻碍了动物实验的扩展，并促进了非动物替代方法的应用。

这些法规的具体影响在近期营运数据中显而易见，数据显示基因改造模型的使用量下降。根据《动物研究概论》（Understanding Animal Research）报道，2024年英国涉及基因改造动物的创建和繁殖的程序数量比去年同期下降了0.5%。这一下降与监管压力增加和市场活动放缓密切相关，因为研究机构和製药公司由于伦理和行政负担日益加重，被迫减少对这些复杂生物模型的依赖。

市场趋势

重塑基因改造动物市场的一项根本性转变是将模型建构工作策略性外包（外包给合约研究组织CRO）。製药公司正加速放弃资本密集的内部育种项目，以减轻维护设施和遵守法规相关的高昂固定成本。这种转变使药物研发人员能够将固定成本转化为可变支出，同时也能获得拥有复杂饲养管理的专业动物族群。这种营运模式转变带来的财务影响在近期主要服务供应商的业绩中清晰可见。 2024年11月，查尔斯河实验室公布第三季财报，其研究模型服务部门的营收成长5.9%，达到1.978亿美元，显示该产业对外部合作伙伴的依赖程度日益加深。

同时，专门用于评估复杂免疫疗法的肿瘤人源化免疫模型正迅速拓展市场。与传统的基因改造生物不同，这些专用平台经过基因工程改造，能够携带功能性的人类免疫系统，使研究人员能够在全身环境下检验查核点抑制剂和抗体药物复合体的疗效。这一趋势区别于一般疾病模型，其重点在于精确地在动物宿主体内重建人类免疫反应，旨在降低转化研究的失败率。 Champions Oncology 等公司推动了这一细分市场的商业性扩张。该公司在 2024 年 12 月公布的 2025 财年第二季财报中显示，其营收成长了 17%，达到 1,350 万美元，这反映出这些专业肿瘤解决方案的普及速度正在加快。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球基因改造动物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（基因枪、PCR、显微注射等）
  • 按PCR类型（即时PCR、数位PCR系统等）
  • 依技术（DNA显微注射、胚胎干细胞介导的基因转殖、逆转录病毒介导的基因转殖等）
  • 依应用领域（重组人类蛋白、单株抗体、异种移植等）
  • 透过模式生物（小鼠、兔子、牛等）
  • 依最终用户（生技/製药公司、学术/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美基因改造动物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲基因改造动物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区基因改造动物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲基因改造动物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲基因改造动物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球基因改造动物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• CH Boehringer Sohn Ko. KG
• ELIAS Animal Health, LLC
• Zoetis Inc.
• AB Science SA
• Karyopharm Therapeutics, Inc.
• Vivesto AB
• Merial Inc.
• Elanco Animal Health, Inc.
• Dechra Pharmaceuticals PLC
• Torigen Pharmaceuticals Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Transgenic Animal Market is projected to expand from USD 4.18 Billion in 2025 to USD 7.63 Billion by 2031, reflecting a compound annual growth rate of 10.55%. This industry involves the commercialization and use of organisms with deliberately altered genetic material to express specific, desirable traits for research or bioproduction. Key factors propelling this expansion include the growing need for predictive animal models to investigate chronic human ailments and the increasing demand for recombinant proteins and monoclonal antibodies within the biopharmaceutical field. Additionally, continuous improvements in gene-editing technologies act as a critical growth engine, allowing for the precise creation of animals that replicate complex physiological states essential for robust drug discovery and development.

Despite these positive drivers, the market faces substantial hurdles due to strict ethical regulations and rising public concern over animal welfare, which can delay regulatory approvals and heighten compliance expenses. Nonetheless, the scientific community continues to rely heavily on these models for essential research. Data from Understanding Animal Research in 2024 indicated that 45% of all regulated scientific procedures in Great Britain were specifically dedicated to creating or breeding genetically altered animals, highlighting the enduring and critical volume of this segment in biomedical innovation.

Market Driver

Breakthroughs in Genome Editing and Engineering Technologies serve as the primary catalyst for the Global Transgenic Animal Market. The integration of high-precision tools, such as CRISPR-Cas9, has revolutionized the capability to engineer animals with specific genetic modifications, enabling the development of organisms with human-compatible organs or precise disease phenotypes. This technological maturation has drawn significant investment, particularly for xenotransplantation applications where genetically modified pigs act as viable organ donors. For instance, eGenesis announced in September 2024 that it secured $191 million in Series D financing to advance its genetically engineered porcine kidney candidate into first-in-human clinical trials, demonstrating strong commercial confidence in these genomic platforms.

Concurrently, the market is significantly bolstered by the escalating demand for predictive preclinical human disease models. With the rise of complex chronic conditions, pharmaceutical developers require sophisticated in vivo systems to screen potential therapies and prevent late-stage clinical failures. In January 2024, the American Cancer Society's "Cancer Facts & Figures 2024" report projected that new cancer cases in the United States would surpass 2 million for the first time, emphasizing the urgent need for advanced oncology models. This disease burden drives massive capital allocation toward discovery pipelines utilizing transgenic organisms; illustrating this scale, Merck & Co. reported a total research and development expenditure of $30.5 billion for the full year 2023 in February 2024, reflecting the immense financial support for biomedical innovation.

Market Challenge

A major obstacle to the Global Transgenic Animal Market's growth is the presence of rigorous ethical regulations and increasing public scrutiny concerning animal welfare. Regulatory bodies worldwide are implementing stricter standards, compelling organizations to undergo exhaustive ethical reviews and strictly adhere to the principles of Replacement, Reduction, and Refinement. These compliance requirements demand significant investment in oversight and documentation, which extends development timelines and raises operational costs, ultimately discouraging the expansion of animal-based research and incentivizing the adoption of non-animal alternative methodologies.

The tangible impact of these restrictions is evident in recent operational data showing a contraction in the utilization of transgenic models. According to Understanding Animal Research, the number of procedures involving the creation and breeding of genetically altered animals in Great Britain decreased by 0.5% in 2024 compared to the previous year. This decline underscores the correlation between intensifying regulatory pressures and the dampening of market activities, as research institutions and pharmaceutical companies are forced to limit their reliance on these complex biological models due to the mounting ethical and administrative burdens.

Market Trends

A fundamental shift reshaping the transgenic animal market is the strategic outsourcing of model generation to Contract Research Organizations. Pharmaceutical firms are increasingly divesting from capital-intensive in-house breeding programs to mitigate the high fixed costs associated with facility maintenance and regulatory compliance. This transition allows drug developers to convert fixed overheads into variable costs while accessing specialized colonies that require complex husbandry. The financial impact of this operational shift is visible in the recent performance of key service providers; Charles River Laboratories reported in November 2024 that revenue for its Research Models and Services segment rose by 5.9% to $197.8 million in its third-quarter results, indicating a growing industry reliance on external partners.

Simultaneously, the market is witnessing a surge in the development of humanized immuno-oncology models specifically designed to evaluate complex immunotherapies. Unlike traditional transgenic organisms, these specialized platforms are engineered to host functional human immune systems, enabling researchers to test the efficacy of checkpoint inhibitors and antibody-drug conjugates in a systemic environment. This trend is distinct from general disease modeling as it focuses on the precise reconstitution of human immunological responses within the animal host to reduce translational failure rates. The commercial expansion of this niche is substantiated by companies like Champions Oncology, which reported a 17% revenue increase to $13.5 million in its fiscal 2025 second-quarter results in December 2024, reflecting the intensifying uptake of these specialized oncology solutions.

Key Market Players

• C.H. Boehringer Sohn Ko. KG
• ELIAS Animal Health, LLC
• Zoetis Inc.
• AB Science S.A.
• Karyopharm Therapeutics, Inc.
• Vivesto AB
• Merial Inc.
• Elanco Animal Health, Inc.
• Dechra Pharmaceuticals PLC
• Torigen Pharmaceuticals Inc

Report Scope

In this report, the Global Transgenic Animal Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transgenic Animal Market, By Product

• Gene Gun
• PCR
• Microinjections
• Others

Transgenic Animal Market, By PCR

• Real-Time PCR
• Digital PCR Systems
• Others

Transgenic Animal Market, By Technique

• DNA Microinjection
• Embryonic Stem Cell-Mediated Gene Transfer
• Retrovirus-Mediated Gene Transfer
• Others

Transgenic Animal Market, By Application

• Recombinant Human Proteins
• Monoclonal Antibodies
• Xenotransplantation
• Others

Transgenic Animal Market, By Model Organisms

• Mice
• Rabbit
• Cow
• Others

Transgenic Animal Market, By End User

• Biotechnology & Pharmaceutical Companies
• Academic & Research Organizations
• Others

Transgenic Animal Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Transgenic Animal Market.

Available Customizations:

Global Transgenic Animal Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Transgenic Animal Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Gene Gun, PCR, Microinjections, Others)
  • 5.2.2. By PCR (Real-Time PCR, Digital PCR Systems, Others)
  • 5.2.3. By Technique (DNA Microinjection, Embryonic Stem Cell-Mediated Gene Transfer, Retrovirus-Mediated Gene Transfer, Others)
  • 5.2.4. By Application (Recombinant Human Proteins, Monoclonal Antibodies, Xenotransplantation, Others)
  • 5.2.5. By Model Organisms (Mice, Rabbit, Cow, Others)
  • 5.2.6. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Organizations, Others)
  • 5.2.7. By Region
  • 5.2.8. By Company (2025)
• 5.3. Market Map

6. North America Transgenic Animal Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By PCR
  • 6.2.3. By Technique
  • 6.2.4. By Application
  • 6.2.5. By Model Organisms
  • 6.2.6. By End User
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Transgenic Animal Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By PCR
      • 6.3.1.2.3. By Technique
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By Model Organisms
      • 6.3.1.2.6. By End User
  • 6.3.2. Canada Transgenic Animal Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By PCR
      • 6.3.2.2.3. By Technique
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By Model Organisms
      • 6.3.2.2.6. By End User
  • 6.3.3. Mexico Transgenic Animal Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By PCR
      • 6.3.3.2.3. By Technique
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By Model Organisms
      • 6.3.3.2.6. By End User

7. Europe Transgenic Animal Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By PCR
  • 7.2.3. By Technique
  • 7.2.4. By Application
  • 7.2.5. By Model Organisms
  • 7.2.6. By End User
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Transgenic Animal Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By PCR
      • 7.3.1.2.3. By Technique
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By Model Organisms
      • 7.3.1.2.6. By End User
  • 7.3.2. France Transgenic Animal Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By PCR
      • 7.3.2.2.3. By Technique
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By Model Organisms
      • 7.3.2.2.6. By End User
  • 7.3.3. United Kingdom Transgenic Animal Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By PCR
      • 7.3.3.2.3. By Technique
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By Model Organisms
      • 7.3.3.2.6. By End User
  • 7.3.4. Italy Transgenic Animal Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By PCR
      • 7.3.4.2.3. By Technique
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By Model Organisms
      • 7.3.4.2.6. By End User
  • 7.3.5. Spain Transgenic Animal Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By PCR
      • 7.3.5.2.3. By Technique
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By Model Organisms
      • 7.3.5.2.6. By End User

8. Asia Pacific Transgenic Animal Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By PCR
  • 8.2.3. By Technique
  • 8.2.4. By Application
  • 8.2.5. By Model Organisms
  • 8.2.6. By End User
  • 8.2.7. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Transgenic Animal Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By PCR
      • 8.3.1.2.3. By Technique
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By Model Organisms
      • 8.3.1.2.6. By End User
  • 8.3.2. India Transgenic Animal Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By PCR
      • 8.3.2.2.3. By Technique
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By Model Organisms
      • 8.3.2.2.6. By End User
  • 8.3.3. Japan Transgenic Animal Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By PCR
      • 8.3.3.2.3. By Technique
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By Model Organisms
      • 8.3.3.2.6. By End User
  • 8.3.4. South Korea Transgenic Animal Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By PCR
      • 8.3.4.2.3. By Technique
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By Model Organisms
      • 8.3.4.2.6. By End User
  • 8.3.5. Australia Transgenic Animal Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By PCR
      • 8.3.5.2.3. By Technique
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By Model Organisms
      • 8.3.5.2.6. By End User

9. Middle East & Africa Transgenic Animal Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By PCR
  • 9.2.3. By Technique
  • 9.2.4. By Application
  • 9.2.5. By Model Organisms
  • 9.2.6. By End User
  • 9.2.7. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Transgenic Animal Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By PCR
      • 9.3.1.2.3. By Technique
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By Model Organisms
      • 9.3.1.2.6. By End User
  • 9.3.2. UAE Transgenic Animal Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By PCR
      • 9.3.2.2.3. By Technique
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By Model Organisms
      • 9.3.2.2.6. By End User
  • 9.3.3. South Africa Transgenic Animal Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By PCR
      • 9.3.3.2.3. By Technique
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By Model Organisms
      • 9.3.3.2.6. By End User

10. South America Transgenic Animal Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By PCR
  • 10.2.3. By Technique
  • 10.2.4. By Application
  • 10.2.5. By Model Organisms
  • 10.2.6. By End User
  • 10.2.7. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Transgenic Animal Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By PCR
      • 10.3.1.2.3. By Technique
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By Model Organisms
      • 10.3.1.2.6. By End User
  • 10.3.2. Colombia Transgenic Animal Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By PCR
      • 10.3.2.2.3. By Technique
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By Model Organisms
      • 10.3.2.2.6. By End User
  • 10.3.3. Argentina Transgenic Animal Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By PCR
      • 10.3.3.2.3. By Technique
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By Model Organisms
      • 10.3.3.2.6. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Transgenic Animal Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. C.H. Boehringer Sohn Ko. KG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ELIAS Animal Health, LLC
• 15.3. Zoetis Inc.
• 15.4. AB Science S.A.
• 15.5. Karyopharm Therapeutics, Inc.
• 15.6. Vivesto AB
• 15.7. Merial Inc.
• 15.8. Elanco Animal Health, Inc.
• 15.9. Dechra Pharmaceuticals PLC
• 15.10. Torigen Pharmaceuticals Inc

16. Strategic Recommendations

17. About Us & Disclaimer